BriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients

Stock Information for Kazia Therapeutics Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kazia Therapeutics Limited

BriaCell Presents Positive Clinical Data at ASCO 2026
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT(TM) at ASCO 2026
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+(TM)
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.